Advice
Following an abbreviated submission
insulin detemir (Levemir®) for injection via the InnoLet® device is accepted for restricted use within NHS Scotland for treatment of diabetes mellitus in patients for whom insulin detemir is an appropriate choice of insulin and who have poor visual acuity and dexterity problems.
The Scottish Medicines Consortium has previously advised that insulin detemir should be restricted to patients attempting to achieve better hypoglycaemic control as there may be some benefit related to a reduced intra-individual variation in glycaemic profile for insulin detemir compared with established insulins.
Download detailed advice33KB (PDF)
Medicine details
- Medicine name:
- insulin detemir, 100 U/ml solution for injection via InnoLet device (Levemir in InnoLet)
- SMC ID:
- 393/07
- Indication:
- diabetes mellitus
- Pharmaceutical company
- Novo Nordisk Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 13 August 2007